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Abstract
Background: Anxiety, depression and functional impairments are commonly reported by persons with multiple
sclerosis (PwMS) but no data, to our knowledge, has emerged from an Arab Islamic population. The study aims
to investigate the prevalence of anxiety, depression and related disabilities among PwMS attending tertiary care
in Sultan Qaboos University Hospital (SQUH), one of the urban hospitals in Oman.
Methods: Consecutive and consenting PwMS (n = 57) and healthy subjects (n = 53) completed the following
measures: Hospital Anxiety and Depression Scale (HADS) which was used to measure anxiety (cut-point >7) and
depression (>7); and Expanded Disability Status Scale (EDSS) to measure the level of disability (≥5). Characteristics
such as socio-demographic and clinical variables were also explored.
Results: Fifty seven subjects with multiple sclerosis (MS) met the inclusion criteria. The majority of them were
females who were 40 years old or younger and the majority were employed and unmarried. Approximately 86 %
of the participants were using beta interferon, 96 % scored ≥5 in EDSS. MS of the Relapsing-Remitting type constituted
the majority of the cohort (94 %). Approximately 35 % and 51 % endorsed symptoms of anxiety and depression
respectively. The MS group scored significantly higher than controls on HADS measurements of depression and
anxiety.
Conclusion: Disability and symptoms of anxiety and depression are common among the PwMS attendees of
tertiary care hospital in Oman. Such psychosocial variables have been largely unreported emerging from non-western
populations. As these variables are strong indicators of the burden of MS, resolute effort is needed to address such
psychosocial dysfunctions in the algorithms of care for PwMS in the Arab Islamic part of the world.
Keywords: Multiple Sclerosis, Anxiety, Depression, Hospital Anxiety and Depression Scale, Expanded Disability Status
Scale, Oman, Arab/Islamic
Background
Multiple Sclerosis (MS) is an inflammatory condition
that tends to have a detrimental effect on cognitive,
emotional and social functioning [1]. It has been esti-
mated that 23.4 per 100,000 people in different popula-
tions around the world are likely to fulfill varying
spectrums of MS [2, 3]. However, there is a discrepancy
in rates of MS, with higher rates being reported among
Caucasian populations and the lowest incidences in sub-
Saharan Africans [4].
According to the Atlas of MS compiled by the Multiple
Sclerosis International Federation and the World Health
Organization [5], the Arabian Gulf, which is geographically
defined as part of the Western Asia region, is a low-risk
zone for MS. This low-risk status remains despite the re-
cent affluence and rising tide of ‘diseases of affluence’ [6]
including MS [7–9] in the region. However, there are emer-
ging epidemiological surveys which are challenging this low
risk hypothesis. Benamer et al. [10] have reviewed studies
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reporting on the rate of MS from Arab populations. Nine-
teen articles have been found from the review covering
publications ranging from 1975 to 2007. The prevalence
rate varied from 4 to 42 per 100,000 people. More recently,
the prevalence and incidence of MS was reported at 85.05
and 6.88 per 100,000 persons in Kuwait respectively [11].
While the magnitude of those affected by MS has been
previously explored, little has been documented on the psy-
chological functioning of persons with multiple sclerosis
(PwMS) in the Arabian Gulf regions.
Some studies in the Arabian Gulf regions indicate clin-
ically heterogeneous diagnoses of MS [12]. Akhtar et al.
[13] have examined correlations of MS among newly di-
agnosed individuals in Qatar. The study indicates that
MS in that particular population is marked by milder
clinical symptoms that tend to be of the ‘relapsing remit-
ting’ type, though with “aggressive radiologic disease
presentation”. The study in Oman reports a high inci-
dence of optic-spinal disease and a negligible rate of oli-
goclonal bands [14]. In this context, the clinical pattern
in Oman resembles Asian populations [14] while the
pattern in Qatar and Iraq appears to be similar to what
is observed in ‘Western’ populations [13, 15]. It is not
clear how far-reaching these different clinical patterns
are in terms of their effect on psychological functioning.
However, a stressful life event has been suggested to ex-
acerbate symptoms of MS [16].
Although MS is a debilitating neurological condition
which tends to trigger psychological symptoms such as
anxiety and depression, no data indicating this has been
searched among PwMS in Arab populations. Depressive
symptoms have been reported to occur in figures that
range from 15 % to above 50 % of PwMS [17–22]. In
addition to depression, variant forms of anxiety disorders
have been reported to be common among PwMS
[23–25]. Korostil and Feinstein [26] examine the pres-
ence of anxiety among 140 consecutive clinic attendees
using the Structured Clinical Interview, as well as the
Hospital Anxiety and Depression (HADS) ‘symptoms
checklist’. The study indicates that approximately 36 %
of the participants were marked with an anxiety disorder,
while approximately 19 % had symptoms of generalized
anxiety disorder. Both depression and anxiety are associ-
ated with impaired social functioning, lower quality of
life and greater utilization of healthcare services which
in turn increases the cost of caring for such a population
[27]. Therefore, establishing a mechanism for the early
diagnosis and intervention of these disorders in PwMS
would be essential. An extensive search on the available
literature reveals that there is a dearth of studies on
anxiety and depression among PwMS in Arabian Gulf.
The present study has embarked with interrelated aims.
The first aim is to audit whether consensus emerging
elsewhere that mood disorders such as depression [21]
and anxiety [28, 29] are common in PwMS holds true
for non-western populations. The specific aim is to ex-
plore the rate of anxiety and depression in a consecutive
sample population of PwMS seeking consultation at a
teaching hospital in Oman. The second aim is to explore
the relationship between the level of mood score on the
HADS symptom checklist with clinical variables and
socio-demographic background. An understanding of
psychosocial variables is important because they have
implications on the outcome of the illness.
Methods
Subjects
A cross-sectional study was conducted during the period
from January 01, 2012 to December 31, 2013, wherein
MS cases were recruited, then compared to subjects
negative for MS. The study used a consecutive sampling
plan procedure, wherein every patient with stable symp-
toms of MS who came for routine consultation at the neur-
ology outpatient clinic at the Sultan Qaboos University
Hospital (SQUH) were enrolled.
SQUH serves an ethnically diverse community located
in the coterminous Muscat governance. Being the only
teaching hospital in Oman and as one of the two referral
centers for neurology in the country, it caters to referrals
from all regions of the country. The annual patient-visit
volume per year for SQUH is in excess of 100,000.
The inclusion criteria constituted those who con-
sented to participate in this study who have fulfilled
MS nomenclature as depicted in McDonald Revised
criteria [30].
Exclusion criteria included those who are suspected to
have concurrent brain disorders, persistent and perva-
sive psychiatric conditions or cognitive impairment or
dementia that would render them incapable of partici-
pating meaningfully in the study. Cognitive impairment
was operationalized as those who scored less than <18
points in the Mini–Mental State Examination (MMSE)
or Folstein Test [31]. Similarly, participants with current
or recent (i.e. within the previous 30 days) MS exacerba-
tions were excluded for rationale that has been outlined
elsewhere [32]. Neurologists who are experienced in
diagnosing and treating MS conducted all the required
neurological evaluations as well as coding each partici-
pant in terms of fulfilling the McDonald Revised criteria
[33]. For the present purpose, the subtypes of MS were
defined as ‘relapsing remitting’, ‘secondary progressive’
and ‘primary progressive’ [33]. Senior medical students
who were unaware of the participants’ clinical features
administered HADS to the consenting participants.
Every person who presented to the clinic with a diagno-
sis of MS was requested to participate, and if consented,
were screened and officially diagnosed using the McDo-
nald Criteria. The medical students, also unaware of the
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patients’ clinical features, administered the MSSE and
HADS tests immediately after the neurology appoint-
ment. This meant that all psychological measures were
administered in one visit.
Participants in the healthy control sample were re-
cruited volunteers from among either relatives of the
client seeking consultation or consenting staff from
the College of Medicine at Sultan Qaboos University.
To qualify as a control sample, the participant was
required to confirm to the researcher that as to his/
her knowledge, she/he is clear of any health conditions
relating to MS.
A total of 126 participants had the potential to be in-
cluded in the study, where 63 were MS cases and the
rest, controls. Out of the total cases, 57 met the inclu-
sion criteria and consented. Two of the MS cases were
excluded because they did not completely fulfill the
McDonald diagnostic criteria, while 3 others refused to
participate. Out of a total of 63 eligible control subjects,
4 refused to participate, and 6 were excluded due to
these reasons: 2 were suspected to have neurological
symptoms, and 4 had incomplete/missing information.
The study was approved by the Medical Research
Committee and the Ethical Committee (MREC#464)
of the College of Medicine and Health Sciences, Sultan
Qaboos University. Participants were asked to sign a
written consent.
Measurement
Hospital Anxiety and Depression Scale (HADS)
Consenting participants were subjected to neurological
examination and administered the Arabic-version of
HADS. Psychometric properties of HADS have been
established in Arabic speaking populations including
Oman [34, 35]. HADS, which is portable and easy-to-
use, measures a person’s current anxiety and depression
levels. Each subscale score ranges from 0 to 21, with
higher scores representing poorer emotional well-being.
A previous study of the Oman’s population had identi-
fied a cut-off point of 8/21 for anxiety or depression. In
a previous study [32], two cut-off scores (i.e., 8/21 and
11/21) were explored for each subscale. For theoretical
reasons, the score of the present participants in the two
cut-off point (8/21 and 11/21) were also explored.
HADS, as specifically designed for clients with general
psychiatric conditions, is sensitive to the probable case-
ness for anxiety or depression in clinical populations
characterized with ‘potential somatic confounders’ [32]
including MS [36, 37].
Degree of disability
Degree of patient disability was also sought using criteria
defined by the Kurtzke Expanded Disability Status Scale
(EDSS) [38]. The EDSS solicits the presence of disability
in eight Functional Systems (FS) which, in turn, are
expressed as a Functional System Score (FSS) in each of
these. The protocol for quantifying disability in PwMS
has been described in detailed elsewhere [39]. In brief,
the progenitor of this measure has operationalized FS to
stem from the integrity of pyramidal, cerebellar, brain-
stem, sensory, bowel and bladder, visual, cerebral and
other bodily systems. EDSS categorizes the severity of
disability ranging from 1 to 10 with a higher score de-
noting a higher index of severity.
In addition to HADS and EDSS, socio-demographic
information as well relevant clinical information was
sought from the referral note, medical records or during
the consultation. Table 1 depicts clinical and socio-
demographic information that was gathered for this
study.
Data analysis
Chi-square analyses were used to evaluate the statistical
significance of differences among proportions of categor-
ical data. The non-parametric Fisher’s exact test (two-
tailed) replaced the Chi-square test in cases of small
sample size, where the expected frequency was less than
5 in any of the cells in 2 x 2 tables. The Independent
Student's t-test and Analysis of Variance (ANOVA)
were used to evaluate the statistical significance of
differences in between means of continuous data. The
non-parametric Wilcoxon Rank test was used to ex-
plore differences of means of continuous variables as
is used in cases of small-sized data. The depression
prevalence estimates were calculated by dividing the
total number of cases with depression by the total
number of the index population.
The binomial distribution method was used to calcu-
late the 95 % confidence intervals (CI) of the rate esti-
mates using the Wald method. The odds ratios (OR)
and 95 % confidence intervals (CI) obtained from logistic
regression models were taken as the measures of associ-
ation between depression and selected socio-demographic
predictors. The following variables were adjusted for
in the regression modeling: gender, education, age,
EDSS score, interferon use, disease duration. All stat-
istical analyses were performed using the Statistical
Package for Social Sciences (SPSS) software (Version 20.0,
IBM, Chicago, Illinois, USA). A significant association is
considered if the 95 % CI does not include the value 1.0;
and a cutoff p-value of less than 0.05 is used for all tests of
statistical significance in this study.
Results
Fifty seven subjects with MS met the inclusion criteria,
and were compared to 53 controls. Table 1 shows the
socio-demographic characteristics of multiple sclerosis
(MS) group versus those of the control group. Overall,
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the MS group tends to include more unmarried females
who are 40 years old or younger. Proportionately, the
MS group tended to be employed and unmarried. The
level of education was comparable among the two
groups.
Table 2 shows the estimates of prevalence of the symp-
toms of anxiety and depression among the cases and
control groups. Among the 57 MS cases, 29 (50.8 %)
were found to suffer from symptoms of anxiety and 20
(35.1 %) to suffer from symptoms of depression; while
among the control group, the proportions of those with
symptoms of anxiety and depression were 35.1 % and
18.9 %, respectively. Both proportions of the symptoms
anxiety and depression were significantly higher among
cases compared to control group (P ≤ 0.05).
Table 3 shows adjusted odds ratio estimates for the
associations between MS and symptoms of anxiety and
depression. The adjusted ORs generated by logistic
regression models indicated that multiple sclerosis was
associated with substantial risks of both symptoms of
Table 1 Socio-demographic and clinical characteristics of persons with multiple sclerosis (PwMS) versus healthy subjects attending a
tertiary hospital, Oman
Characteristics Total (N = 110) PwMS (N = 57) Healthy subjects (N = 53) P value
N (%) N (%) N (%)
Gender 0.04
Female 63 (57.3) 41 (71.9) 22 (41.5)
Male 47 (42.7) 16 (28.1) 31 (58.5)
Age 0.05
40 or less 91 (82.7) 51 (89.5) 40 (75.5)
More than 40 19 (17.3) 6 (10.5) 13 (24.5)
Education 0.99
12 years or less 54 (49.1) 28 (49.1) 26 (49.1)
More than 12 years 56 (50.9) 29 (50.9) 27 (50.9)
Marital status
Unmarried 64 (58.2) 35 (61.4) 29 (54.7)
Married 46 (41.8) 22 (38.6) 24 (45.3) 0.04
Employment
Employed 51 (46.3) 7 (12.3) 44 (83.1) 0.02








Relapsing Remitting (RR) 54 (94.7)
Secondary Progressive (SR) 1 (1.8)
Primary Progressive (PR) 2 (3.5)
Table 2 Estimated prevalence (95 % CI) of anxiety and depression among persons with multiple sclerosis (PwMS) and Healthy
Subjects attending a tertiary hospital, Oman
Outcome Case (N = 57) Healthy subjects (N = 53) P value
N (%) P* (95 % CI) N (%) P* (95 % CI)
Anxiety 29 (50.8) 50.8 (38.3, 63.4) 14 (26.4) 26.4 (16.3, 39.7) 0.01
Depression 20 (35.1) 35.1 (24.0, 48.1) 10 (18.9) 18.9 (10.4, 31.6) 0.05
*P: Prevalence estimate is per 100 patients
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anxiety (OR = 2.43; 95 % CI 1.13, 6.82; P = 0.03) and de-
pression (OR = 2.11; 95 % CI 0.92, 6.72; P = 0.07).
Table 4 compares the anxiety and depression scores
according to HADS in between MS case versus control
groups. Overall, the HADS scores on anxiety among MS
patients were significantly higher (8.3 vs. 4.9) than that
among the control group (P = 0.04). A similar pattern
was also observed along the HADS scores on depression
(6.5 vs. 4.1; P = 0.05). This pattern of observing higher
scores among MS cases compared to controls was also
persistent upon further stratifying HADS scores accord-
ing to proposed cutoffs (i.e. 8/21) which identified
pathological HADS scores.
Table 5 shows the associations between HADS scores
for anxiety and depression and selected socio-
demographic and clinical characteristics. On average,
higher scores of anxiety on HADS were reported among
participants who were female, married, employed, and
with more than 12 years of education. Clinically, higher
scores of HADS on anxiety were associated with no in-
take of interferon, EDSS greater than 5, and secondary
progressive MS. Higher scores of HADS on depression
were reported among participants with similar socio-
demographic and clinical characteristics to those ob-
served with HADS on anxiety, except that they were
higher among participants who were unmarried and
with less than 12 years of education.
Table 6 shows the associations between probable for
depression and selected factors as obtained from multi-
variate logistic regression. Overall, a slight increase in
risk of pathological depression was observed with ad-
vanced age, female gender, and less education. A more
substantial increase in risk of pathological depression
was observed with increased duration of disease (OR =
2.32; 95 % CI 0.52, 7.53) and EDSS >5 (OR = 5.83; 95 %
CI 0.26, 9.4). Nonetheless, all obtained associations were
not statistically significant (P-value >0.05).
Discussion
The first aim of this study was to examine whether anx-
iety and depressive symptoms that are common in
PwMS in Euro-American populations [21, 37, 40] are
also present in cases in Oman. To our knowledge, there
is a dearth of studies examining the presence of psycho-
logical distress in PwMS in Arabian Gulf countries, and
Oman is no exception. Previous studies have shown that
anxiety and depressive symptoms are common in vari-
ous clinical populations in Oman [34, 35].
The present study indicates that 50.8 % of the partici-
pants endorse themselves as having depressive symp-
toms, according to the cut-off point of HADS. Studies
from other populations have indicated that 29-54 % of
PwMS tend to exhibit various spectrums of depressive
illness [17, 41]. Many factors could determine the wide
variations in the rate of depressive symptoms, including
the different types of instruments employed to quantify
the presence of depression as well as the heterogeneous
cohorts employed. It is worthwhile to note the rate of
depressive symptoms in the present study falls in the
range of earlier studies that have utilized HADS [42].
This study indicates that 35 % of PwMS manifest anx-
iety symptoms. These results are similar to a study re-
ported by Smith and Young in the United Kingdom [43],
where they found that among 88 consecutive PwMS,
Table 3 Adjusted odds ratios (95 % CI) of associations between
multiple sclerosis and each of anxiety and depression as
quantified by the Hospital Anxiety and Depression Scale among
attendees of a tertiary hospital in Oman
Variable ORa 95 % CI P value
Anxiety 2.43 1.13, 6.82 0.03
Depression 2.11 0.92, 6.72 0.07
aAdjusted odds ratio estimates were generated by considering the
confounding effects of age, gender, marital status, and employment status
Table 4 Performance of anxiety and depression sub-scale of Hospital Anxiety and Depression Scale (HADS) among persons with
multiple sclerosis (PwMS) versus Healthy subjects attending a tertiary hospital in Oman
Characteristics PwMS (N = 57) Healthy subjects (N = 53) P value
N (%) or mean (SD) N (%) or mean (SD)
HADS (Anxiety)
Mean (SD) 8.3 (4.8) 4.9 (4.7) 0.04
Group- n (%)
≥11 22 (38.6) 9 (17.0) 0.07
≥8 31 (54.4) 15 (28.3) 0.04
HADS (Depression)
Mean (SD) 6.5 (5.1) 4.1 (4.4) 0.05
Group- n (%)
≥11 12 (21.1) 7 (13.2) 0.08
≥8 22 (38.6) 12 (22.6) 0.06
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34 % scored in the clinical range in the anxiety subscale
of HADS.
The present observation that the rate of depressive
and anxiety symptoms as endorsed by the HADS scale
in PwMS in tertiary care in Oman is common raises an
interesting discourse. According to some commentators
(e.g. Dwairy [44]), Arab societies tend to lean towards a
‘collective’ social orientation which is contrasted to indi-
vidualistic social orientation commonly found in West-
ern countries. In order to preserve social harmony, such
a society tends to discourage the expression of emotion
and therefore relegates emotional distress. Instead, dis-
tress is expressed in somatic terms, a feat that is orthog-
onal to what may constitute emotional distress in the
psychiatric nomenclature such as Diagnostic and Statis-
tical Manual of Mental Disorders (DSM) [45] and the
International Statistical Classification of Diseases and
Related Health Problems (ICD-10) [46]. Within such a
context, an examination of anxiety and depressive symp-
toms in non-Western societies is hampered by the fact
Table 5 Factors associated with each subscales of Hospital Anxiety and Depression Scale depression (HADS) among of persons with
multiple sclerosis (n = 57 attending a tertiary hospital in Oman
HADS Anxiety HADS Depression
Mean (SD) P value Mean (SD) P value
Sex 0.03 0.27
Female 7.3 (5.0) 5.7 (4.6)
Male 5.3 (4.9) 4.8 (4.6)
Educational level 0.02 0.12
≤12 years 6.1 (5.1) 5.6 (4.8)
>12 years 6.8 (4.9) 5.1 (4.3)
Marital status 0.12 0.08
Unmarried 6.3 (5.2) 5.8 (4.5)
Married 6.8 (4.8) 5.2 (4.6)
Employment 0.01 0.32
Employed 8.2 (4.8) 6.2 (4.2)
Unemployed 5.8 (4.9) 5.3 (4.9)
Interferon 0.24 0.09
Yes 7.9 (4.8) 6.3 (4.4)
No 10.1 (4.7) 9.2 (4.1)
EDSS 0.06 0.21
≤5 8.1 (4.7) 6.5 (4.3)
>5 14.5 (3.7) 10.5 (3.5)
Course of disease 0.13 0.26
Relapsing remitting (RR) 8.1 (4.7) 6.7 (4.4)
Secondary progressive (SP) 14.0 11.5
Primary progressive (PP) 3.0 (1.2) 4.0 (1.1)
Table 6 Factors associated with HADS depression scores (cut-off 8/21) among of persons with multiple sclerosis (n = 57) attending a
tertiary hospital in Oman
Variable Odds ratio (95 % CI)
Mean (SD) Crude P-value Adjusted P-value
Age > 40 years 5.6 (4.1) 1.58 (0.48, 5.23) 0.45 1.28 (0.13, 7.33) 0.83
Female gender 5.7 (4.6) 1.32 (0.48, 3.63) 0.58 1.14 (0.24, 5.32) 0.87
Education≤ 12 years 5.6 (4.8) 1.05 (0.63, 1.76) 0.85 1.13 (0.57, 2.26) 0.71
Disease duration≥ 5 years 6.9 (4.5) 1.46 (0.40, 5.31) 0.56 2.32 (0.52, 7.53) 0.28
No use of interferon 9.2 (4.1) 3.28 (0.21, 6.8) 0.29 3.91 (0.23, 7.9) 0.24
EDSS score > 5 10.5 (3.5) 4.20 (0.24, 7.3) 0.32 5.83 (0.26, 9.4) 0.27
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that symptoms are articulated differently. Rather than
simply relying on the established cut-off point for HADS
to identify the presence of anxiety and depressive symp-
toms in PwMS in Oman, the present study uses eco-
logical validity by comparing the performance of HADS
with healthy participants. Within such a comparison, the
present data unequivocally suggests that PwMS have
higher scores in anxiety and depressive symptoms com-
pared to healthy controls. The present study challenges
the assumption that people in non-Western societies are
devoid of emotional distress.
There is a debate on the ‘origin’ of anxiety and depres-
sive symptoms in PwMS. One hypothesis suggests that
pathophysiological processes that are an integral part of
MS tend to trigger anxiety and depressive symptoms
[47, 48]. Functional neuroimaging data have suggested
that attenuation of the activities in frontal and temporal
lobes of the right hemisphere does not only correlate
with presence of MS but also the occurrence of anxiety
and depressive symptoms [49, 50]. The alternative hypoth-
esis is that anxiety and depressive symptoms in MS are a
reaction to living with MS. Regardless of whether it is a re-
action or an integral part of MS, the much ignored psycho-
logical need of those PwMS should be considered in the
algorithm of care for the disease. Along with establishing
psychological services, studies are needed to shed light on
how anxiety and depressive symptoms among PwMS are
perceived in Oman’s society.
The second aim of this study was to explore the rela-
tionship between anxiety and depressive symptoms with
clinical and socio-demographic variables. The partici-
pants who scored highly for both anxiety and depressive
symptoms appear to have similar clinical characteristics,
for example, having been treated with interferon, having
a high level of disability as quantified by an EDSS
(score > 5) and fulfilling the diagnosis for ‘Secondary
Progressive’ type MS. Other correlations are worth
highlighting. HADS scores on both anxiety and depres-
sion were found to be markedly higher in females, a feat
that is congruent with the international trend [51]. The
present study indicates that higher scores in indices of
anxiety are more common among married females, in
particular, amongst those who have achieved more than
12 years of education. In emerging economies such as
the one found in Oman, women are often required to
juggle between career and family life [52] and all the
stress and anxiety it may entail. In contrast, a depressive
symptom was found to be higher in unmarried females
with a lower educational attainment. In traditional
Omani society, it is stated that ‘a wedding is a blessed
garment’ which, in turn, implicitly stigmatizes unmarried
women [53]. It is also worthwhile to note that this study
found that the majority of participants were unmarried.
On the whole, the view that there is a preponderance of
unmarried people among PwMS has also been reported
in other populations [54]. It is possible that sexual dys-
function is common in PwMS [55, 56] and the disability
it entails may render these women as ineligible for mar-
riage in Omani society.
The study should be viewed as a sentinel project and
therefore some obvious limitations need to be highlighted.
Firstly, the cohort was a convenient sample and could be a
biased sample of self-selective people who were referred to
tertiary care in an urban area. Such biased sample and the
nature of catchment area hamper the generalization of this
study. Secondly, although HADS appeared to be valid for
use in the Omani population [34, 57], the HADS test has
not been standardized for Arabic speaking PwMS. Similarly,
HADS is marred with limitations when compared to a
semi-structured interview since, for example, it is known to
solicit the presence of ‘hedonic tone’ rather than other
characteristics of depression such as hopelessness, guilt and
low self-esteem [57].
The presently observed rate of anxiety and depressive
symptoms present potential ‘case-ness’ since the ‘gold
standard interview’ was not employed. It is worthwhile
to note that HADS provides a quick screen, not a diag-
nosis. The present observed rate appears to echo inter-
national standards even to those studies that have
utilized the gold standard interview. The third limitation
of this study stems from the conspicuous absence of
measures that solicit the presence of fatigue. There is
ample evidence suggesting that fatigue tends to influence
psychological state and vice-versa [58] and many avail-
able scales are ‘contaminated’ by the MS symptoms such
as tiredness and impaired cognition. This is likely to
dent the reliability of the instrument in eliciting the
symptoms of anxiety or depression [59]. Future studies
should examine whether depression and fatigue are ‘twin
sisters’ with overlapping or orthogonal symptoms [60].
Additionally, this study would have had higher heuristic
value if the participant’s duration of symptoms were
established. Future studies could address these limita-
tions. On the whole, larger studies possibly with age and
gender matched controls, with formal confirmation of
emotional changes of those patients with positive
screening scores, stratification of patients based for ex-
ample on disease duration, etc. may provide more robust
information regarding the prevalence and possibly the
risk factors for depression and anxiety in MS.
Conclusion
To our knowledge, this is the first study to explore psycho-
social variables in PwMS in an Arab/Islamic population. The
findings is congruent with international trends in terms of
the magnitude of anxiety and depressive symptoms. Simi-
larly, various correlates of anxiety and depressive symptoms
observed in the present study appear to echo the
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international trend with slight variation due to socio-cultural
factors. The present findings have various implications. A
larger study with more robust methodology is needed to
scrutinize the present findings so that a concerted effort can
be contemplated to improve the psychosocial services for
PwMS, including detection and culturally sensitive psycho-
logical interventions. In many non-Western cultures, there
is a tendency to neglect these services for clients with
chronic illnesses. This study suggests that psychological dis-
orders are common in PwMS. Therefore, development of
services to attend to their psychological disorders is
warranted.
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